Loading…
Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy
Background The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment. Methods A tota...
Saved in:
Published in: | Clinical and experimental nephrology 2021-05, Vol.25 (5), p.488-500 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83 |
---|---|
cites | cdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83 |
container_end_page | 500 |
container_issue | 5 |
container_start_page | 488 |
container_title | Clinical and experimental nephrology |
container_volume | 25 |
creator | Yeter, Hasan H. Isik Gonul, Ipek Eraslan, Esra Karacalik, Ceren Ogut, Betul Guz, Galip |
description | Background
The aim of this study was to define the clinicopathologic features of phospholipase A
2
receptor (PLA
2
R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment.
Methods
A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA
2
R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated.
Results
PLA
2
R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA
2
R positive and negative patients, collectively. Glomerular PLA
2
R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA
2
R negative patients (
p
= 0.2 and
p
= 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA
2
R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA
2
R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission.
Conclusions
The probability of achieving complete remission is high in patients with PLA
2
R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA
2
R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials. |
doi_str_mv | 10.1007/s10157-020-02011-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2478773877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478773877</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoO44DrrC3gKePGSNdX_0jkOy6oLC170HDJJ9Uwv3UmbpMF5PN_M6p0FwYOHokL4fV9V8TH2HuQtSKk-ZZDQKiEruRWA6F6xa2hqJZTS-jW966YSoFp4w97m_CSl7HWrr9nv-2FAVzKPA19OMVNN42Iz8n3FEzpcSkzcBs_LKcX5QEQMfgy8nBcUwH2c7RiEi6FQH8ORqz3HX0vCnMcYOJHHKc6Y1skmfiDjGUPhM86HZAPSXLJKaMvzN6nInoZvAxMGO_G4Fkf6zehFFNfMAy60zmLL6XzDrgY7ZXz30nfsx-f773dfxeO3Lw93-0fh6qbrRGUb7ayXrdRNB8PQDupgETX0ukaJjfPgtZO-bb3vaoCqt1Wte607O1Tg-3rHPl58lxR_rpiLmcfscJroDFrJVI3qlaq32rEP_6BPcU10DVEtSK01ZURUdaFcijknHMySxtmmswFptlTNJVVDiZrnVE1HovoiygSHI6a_1v9R_QFrnam6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2510999201</pqid></control><display><type>article</type><title>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</title><source>Springer Link</source><creator>Yeter, Hasan H. ; Isik Gonul, Ipek ; Eraslan, Esra ; Karacalik, Ceren ; Ogut, Betul ; Guz, Galip</creator><creatorcontrib>Yeter, Hasan H. ; Isik Gonul, Ipek ; Eraslan, Esra ; Karacalik, Ceren ; Ogut, Betul ; Guz, Galip</creatorcontrib><description>Background
The aim of this study was to define the clinicopathologic features of phospholipase A
2
receptor (PLA
2
R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment.
Methods
A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA
2
R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated.
Results
PLA
2
R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA
2
R positive and negative patients, collectively. Glomerular PLA
2
R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA
2
R negative patients (
p
= 0.2 and
p
= 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA
2
R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA
2
R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission.
Conclusions
The probability of achieving complete remission is high in patients with PLA
2
R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA
2
R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-020-02011-6</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Basement membranes ; Biopsy ; Clinical trials ; End-stage renal disease ; Immunoglobulin G ; Kidney diseases ; Medicine ; Medicine & Public Health ; Membranous nephropathy ; Nephrology ; Nephropathy ; Original Article ; Patients ; Phospholipase A2 ; Remission ; Thrombospondin ; Urology</subject><ispartof>Clinical and experimental nephrology, 2021-05, Vol.25 (5), p.488-500</ispartof><rights>Japanese Society of Nephrology 2021</rights><rights>Japanese Society of Nephrology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</citedby><cites>FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</cites><orcidid>0000-0002-5787-1048</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Yeter, Hasan H.</creatorcontrib><creatorcontrib>Isik Gonul, Ipek</creatorcontrib><creatorcontrib>Eraslan, Esra</creatorcontrib><creatorcontrib>Karacalik, Ceren</creatorcontrib><creatorcontrib>Ogut, Betul</creatorcontrib><creatorcontrib>Guz, Galip</creatorcontrib><title>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><description>Background
The aim of this study was to define the clinicopathologic features of phospholipase A
2
receptor (PLA
2
R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment.
Methods
A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA
2
R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated.
Results
PLA
2
R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA
2
R positive and negative patients, collectively. Glomerular PLA
2
R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA
2
R negative patients (
p
= 0.2 and
p
= 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA
2
R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA
2
R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission.
Conclusions
The probability of achieving complete remission is high in patients with PLA
2
R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA
2
R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.</description><subject>Basement membranes</subject><subject>Biopsy</subject><subject>Clinical trials</subject><subject>End-stage renal disease</subject><subject>Immunoglobulin G</subject><subject>Kidney diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Membranous nephropathy</subject><subject>Nephrology</subject><subject>Nephropathy</subject><subject>Original Article</subject><subject>Patients</subject><subject>Phospholipase A2</subject><subject>Remission</subject><subject>Thrombospondin</subject><subject>Urology</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc-KFDEQxoO44DrrC3gKePGSNdX_0jkOy6oLC170HDJJ9Uwv3UmbpMF5PN_M6p0FwYOHokL4fV9V8TH2HuQtSKk-ZZDQKiEruRWA6F6xa2hqJZTS-jW966YSoFp4w97m_CSl7HWrr9nv-2FAVzKPA19OMVNN42Iz8n3FEzpcSkzcBs_LKcX5QEQMfgy8nBcUwH2c7RiEi6FQH8ORqz3HX0vCnMcYOJHHKc6Y1skmfiDjGUPhM86HZAPSXLJKaMvzN6nInoZvAxMGO_G4Fkf6zehFFNfMAy60zmLL6XzDrgY7ZXz30nfsx-f773dfxeO3Lw93-0fh6qbrRGUb7ayXrdRNB8PQDupgETX0ukaJjfPgtZO-bb3vaoCqt1Wte607O1Tg-3rHPl58lxR_rpiLmcfscJroDFrJVI3qlaq32rEP_6BPcU10DVEtSK01ZURUdaFcijknHMySxtmmswFptlTNJVVDiZrnVE1HovoiygSHI6a_1v9R_QFrnam6</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Yeter, Hasan H.</creator><creator>Isik Gonul, Ipek</creator><creator>Eraslan, Esra</creator><creator>Karacalik, Ceren</creator><creator>Ogut, Betul</creator><creator>Guz, Galip</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5787-1048</orcidid></search><sort><creationdate>20210501</creationdate><title>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</title><author>Yeter, Hasan H. ; Isik Gonul, Ipek ; Eraslan, Esra ; Karacalik, Ceren ; Ogut, Betul ; Guz, Galip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Basement membranes</topic><topic>Biopsy</topic><topic>Clinical trials</topic><topic>End-stage renal disease</topic><topic>Immunoglobulin G</topic><topic>Kidney diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Membranous nephropathy</topic><topic>Nephrology</topic><topic>Nephropathy</topic><topic>Original Article</topic><topic>Patients</topic><topic>Phospholipase A2</topic><topic>Remission</topic><topic>Thrombospondin</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeter, Hasan H.</creatorcontrib><creatorcontrib>Isik Gonul, Ipek</creatorcontrib><creatorcontrib>Eraslan, Esra</creatorcontrib><creatorcontrib>Karacalik, Ceren</creatorcontrib><creatorcontrib>Ogut, Betul</creatorcontrib><creatorcontrib>Guz, Galip</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeter, Hasan H.</au><au>Isik Gonul, Ipek</au><au>Eraslan, Esra</au><au>Karacalik, Ceren</au><au>Ogut, Betul</au><au>Guz, Galip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><date>2021-05-01</date><risdate>2021</risdate><volume>25</volume><issue>5</issue><spage>488</spage><epage>500</epage><pages>488-500</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><abstract>Background
The aim of this study was to define the clinicopathologic features of phospholipase A
2
receptor (PLA
2
R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment.
Methods
A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA
2
R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated.
Results
PLA
2
R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA
2
R positive and negative patients, collectively. Glomerular PLA
2
R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA
2
R negative patients (
p
= 0.2 and
p
= 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA
2
R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA
2
R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission.
Conclusions
The probability of achieving complete remission is high in patients with PLA
2
R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA
2
R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><doi>10.1007/s10157-020-02011-6</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-5787-1048</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1342-1751 |
ispartof | Clinical and experimental nephrology, 2021-05, Vol.25 (5), p.488-500 |
issn | 1342-1751 1437-7799 |
language | eng |
recordid | cdi_proquest_miscellaneous_2478773877 |
source | Springer Link |
subjects | Basement membranes Biopsy Clinical trials End-stage renal disease Immunoglobulin G Kidney diseases Medicine Medicine & Public Health Membranous nephropathy Nephrology Nephropathy Original Article Patients Phospholipase A2 Remission Thrombospondin Urology |
title | Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A45%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20phospholipase%20A2%20receptor%20and%20thrombospondin%20type-1%20domain-containing%207A%20expression%20in%20glomerular%20basement%20membranes%20on%20treatment%20response%20and%20renal%20outcome%20in%20membranous%20nephropathy&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Yeter,%20Hasan%20H.&rft.date=2021-05-01&rft.volume=25&rft.issue=5&rft.spage=488&rft.epage=500&rft.pages=488-500&rft.issn=1342-1751&rft.eissn=1437-7799&rft_id=info:doi/10.1007/s10157-020-02011-6&rft_dat=%3Cproquest_cross%3E2478773877%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2510999201&rft_id=info:pmid/&rfr_iscdi=true |